News
Terns Pharma files $125m+ public offering to support trials of its oral GLP-1 agonist candidate TERN-601 for obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback